Fractyl Health (GUTS) risk factors, FY2024 10-K

Risks Related to Our Financial Condition and Capital Requirements

1. 01We have incurred significant net losses since inception and we expect to continue to incur significant net losses for the foreseeable future and may never achieve or sustain profitability
2. 02commercializing one or more of our product candidates, we expect that we will continue to incur substantial research and development and other expenses as we discover, develop and market additional potential product candidates
3. 03operate as a public company
4. 04have paused investment in our Revita programs for T2D, consisting of the REVITALIZE-1 study and the Germany Real-World Registry study
5. 05the cost of operating as a public company
6. 06Our credit agreement contains restrictive and financial covenants that may limit our operating flexibility
7. 07Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidates on unfavorable terms to us
8. 08Our ability to utilize our net operating loss carryforwards, research and development tax credit carryforwards, and certain other tax attributes to offset taxable income or taxes may be limited

Risks Related to Development, Regulatory Approval and Commercialization

1. 09changes in the approval or certification policies or regulations that render our preclinical and clinical data insufficient for approval or certification
2. 10Clinical studies are expensive, time-consuming, difficult to design and implement, and have an uncertain outcome. Further, we may encounter substantial delays in our clinical studies
3. 11failure to manufacture sufficient quantities of product candidates for use in clinical studies
4. 12have the product removed from the market after obtaining marketing approval or certification
5. 13We currently conduct and may in the future conduct clinical studies for our product candidates outside the United States, and the FDA or comparable foreign regulatory authorities may not accept data from such studies
6. 14We may not be able to submit IDEs or IDE supplements or comparable documents in foreign jurisdictions to commence additional clinical studies on the timelines we expect, and even if we are able to, the FDA or comparable foreign regulatory authorities may not permit us to proceed
7. 15there is reason to believe that the device as used is ineffective; or
8. 16the monitoring and review of the investigation
9. 17We may not be able to submit INDs or IND amendments, CTAs or comparable documents in foreign jurisdictions to commence additional clinical studies on the timelines we expect, and even if we are able to, the FDA or other comparable foreign regulatory authorities may not permit us to proceed
10. 18Interim, topline and preliminary data from our clinical studies that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
11. 19Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved or certified, and could seriously harm our business
12. 20Although Revita has received Breakthrough Device designations, there can be no guarantee that the designation will benefit the development and regulatory approval process
13. 21If healthcare providers are unable to obtain coverage or adequate reimbursement for procedures performed with our products, if approved, such products will not likely be widely used
14. 22acceptance of our existing and future products. Neither hospitals nor physicians are likely to use our product, if approved, and any future products if they do not receive adequate reimbursement for the procedures utilizing such products
15. 23Additional time may be required to develop and obtain regulatory approval or certification for our Rejuva gene therapy candidates because we expect it to be regulated as a combination product
16. 24Obtaining and maintaining regulatory approval or certification of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval or certification of our product candidates in other jurisdictions
17. 25injunctions or the imposition of civil or criminal penalties
18. 26We expect our Rejuva gene therapy candidates will be, and future gene therapy candidates may be, regulated as biological products, or biological product-device combination products, and therefore may be subject to competition sooner than anticipated
19. 27In addition, the approval of a biologic product biosimilar to one of our product candidates could have a material adverse impact on our business as it may be significantly less costly to bring to market and may be priced significantly lower than our products
20. 28A recall of our products, if approved, either voluntarily or at the direction of the FDA or another governmental authority, or the discovery of serious safety issues with our products, could have a significant adverse impact on us
21. 29If we obtain approval or certification of any of our product candidates, we may be subject to enforcement action if we engage in the off-label promotion of our products

Risks Related to Our Business and Strategy

1. 30We are substantially dependent on the success of our lead product candidate, Revita. If we are unable to obtain marketing approval or certification for and commercialize any of our current or future product candidates in a timely manner, our business will be harmed
2. 31our ability to compete with other therapies
3. 32any potential interruptions or delays resulting from factors related to any future public health crises, including epidemics and pandemics
4. 33We have not yet studied the ability of Revita to be used in repeated procedures. If we are unable to demonstrate the safety and improved glycemic effects of Revita for repeat use, it could have a material adverse effect on the clinical utility and commercial adoption of the device
5. 34We have never obtained marketing approval for a product candidate in the United States and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any product candidate in the United States
6. 35additional studies, if performed and completed, may not be considered sufficient by the FDA to approve our PMA applications or BLAs
7. 36If Revita, our Rejuva gene therapy candidates or any of our other future product candidates is approved or certified and fail to achieve and sustain sufficient market acceptance, we will not generate expected revenue and our business may be harmed
8. 37the additional time commitment that may be required for training
9. 38Our future growth depends on physician awareness and adoption of the Revita DMR procedure
10. 39The training required for endoscopists to use Revita could reduce the market acceptance of our products
11. 40We have never commercialized a product candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize any products on our own or together with suitable collaborators
12. 41better-established, larger-scale and lower-cost manufacturing capabilities and supplier relationships
13. 42technical superiority of the Revita DMR procedure in comparison to current treatment options
14. 43We may not be able to develop new product candidates or enhance the capabilities of our existing product candidates to keep pace with our industry’s rapidly changing technology and customer requirements, which could have a material adverse impact on our revenue, results of operations and business
15. 44If the market opportunity for any product candidate that we develop is smaller than we believe, our revenue may be adversely affected and our business may suffer
16. 45If the quality of our product candidates does not meet the expectations of diabetologists, gastroenterologists, interventional endoscopists, endocrinologists, PCPs or other referring physicians, or patients, then our brand and reputation could suffer and our business could be adversely impacted
17. 46Our sales cycle will be lengthy and variable, which makes it difficult for us to forecast revenue and other operating results
18. 47Third-party payors may choose not to cover the DMR procedure using Revita or they may require extensive and/or independently performed clinical studies prior to covering or maintaining coverage of the DMR procedure using Revita
19. 48We depend on our information technology systems, and any failure of these systems could harm our business

Risks Relating to Our Dependence on Third Parties

1. 49we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects
2. 50If we decide to establish new collaborations in the future, but are not able to establish those collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans
3. 51We may enter into collaborations in the future with third parties for the development and commercialization of product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates
4. 52Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements

Risks Related to Manufacturing

1. 53geopolitical or macroeconomic factors
2. 54If we or our suppliers fail to comply with the FDA’s good manufacturing practice regulations, this could impair our ability to market our products in a cost-effective and timely manner
3. 55Any of these sanctions could have a material adverse effect on our reputation, business, results of operations and financial condition
4. 56We depend on third-party sole-source suppliers for certain sub-assembly components of Revita, and any interruption in our relationship with such third-party sole-source suppliers may materially adversely affect our business
5. 57Changes in methods of our Rejuva gene therapy candidate manufacturing or formulation may result in additional costs or delay
6. 58significant changes to our upstream and downstream processes across our pipeline, which could delay the development of any future gene therapy candidates
7. 59If our facilities are damaged or become inoperable, we will be unable to continue to research, develop and manufacture our product candidates and, as a result, there will be an adverse impact on our business until we are able to secure a new facility

Risks Related to Legal and Regulatory Compliance Matters

1. 60We face the risk of product liability claims that could be expensive, divert management’s attention and harm our reputation and business. We may not be able to maintain adequate product liability insurance
2. 61We are subject to applicable fraud and abuse, transparency, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties
3. 62Healthcare reform initiatives and other administrative and legislative proposals in the United States may adversely affect our business, financial condition, results of operations and cash flows
4. 63expanded the eligibility criteria for Medicaid programs
5. 64the availability of capital
6. 65We may not be able to successfully commercialize our product candidates due to unfavorable pricing regulations or third-party coverage and reimbursement policies, which could make it difficult for us to sell our product candidates profitably
7. 66neither experimental nor investigational
8. 67Changes in and actual or perceived failures to comply with U.S. and foreign privacy and data protection laws, regulations and standards may adversely affect our business, operations and financial performance
9. 68We are subject to complex and changing laws and regulations, which exposes us to potential liabilities, increased costs and other adverse effects on our business
10. 69Damage to our reputation or brand image could adversely affect our sales and results of operations

Risks Related to Our Intellectual Property

1. 70We will not seek to protect our intellectual property rights in all jurisdictions throughout the world and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection
2. 71Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities
3. 72Our commercial success depends significantly on our ability to operate without infringing, misappropriating or otherwise violating the intellectual property rights of third parties
4. 73relinquish rights associated with one or more of our patent claims, if our claims are held invalid or unenforceable
5. 74Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our existing and future product candidates and technologies
6. 75Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
7. 76Patent terms may not be sufficient to effectively protect our product candidates and business for an adequate period of time
8. 77If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
9. 78If we are unable to protect the confidentiality of our trade secrets and other proprietary information, our business and competitive position may be harmed
10. 79We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property
11. 80We may enter into licenses to intellectual property. If we were to lose our rights to licensed intellectual property, we may not be able to continue developing or commercializing a product candidate, if approved, that relied on such licensed intellectual property
12. 81and defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our drugs that are subject of such licensed rights could be adversely affected
13. 82the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners
14. 83Numerous factors may limit any potential competitive advantage provided by our intellectual property rights

Risks Related to Employee Matters and Managing Our Growth

1. 84If we are unable to establish sales or marketing capabilities or enter into agreements with third parties to sell or market our product candidates, we may not be able to successfully sell or market our product candidates that obtain regulatory approval
2. 85Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees
3. 86In order to successfully implement our plans and strategies, including our Strategic Reprioritization we will need to grow the size of our organization, and we may experience difficulties in managing this growth
4. 87improving our operational, financial and management controls, reporting systems and procedures
5. 88able to obtain marketing approval of any current or future product candidates or otherwise advance our business. We cannot assure you that we will be able to manage our existing third party service providers or find other competent outside contractors and consultants on economically reasonable terms, or at all

Risks Related to Ownership of Our Common Stock

1. 89The price of our stock may be volatile, and you could lose all or part of your investment
2. 90general economic, geopolitical, industry and market conditions
3. 91If securities or industry analysts do not publish research or reports, or if they publish adverse or misleading research or reports, regarding us, our business or our market, our stock price and trading volume could decline
4. 92Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval
5. 93Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall
6. 94ourselves or our other stockholders. Once we register the offer and sale of shares for the holders of registration rights, these shares will be able to be sold in the public market
7. 95We do not currently intend to pay dividends on our common stock and, consequently, your ability to achieve a return on your investment will depend on appreciation of the value of our common stock
8. 96Provisions in our certificate of incorporation and bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock
9. 97require a super-majority vote of stockholders to amend some provisions described above

General Risks

1. 98Our operations are vulnerable to interruption by fire, severe weather conditions, power loss, telecommunications failure, terrorist activity, future pandemics and other events beyond our control, which could harm our business
2. 99We are an “emerging growth company,” and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors
3. 100We cannot predict if investors will find our common stock less attractive because we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile
4. 101We are a “smaller reporting company” and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors
5. 102The requirements of being a public company may strain our resources, result in more litigation and divert management’s attention
6. 103Changes in our effective tax rate or tax liability may have an adverse effect on our results of operations
7. 104If our product candidates are approved, we expect to generate a portion of our future revenue internationally and are subject to various risks relating to international operations, which could adversely affect our operating results
8. 105existence of additional third-party intellectual property rights of potential relevance
9. 106New tax legislation may impact our results of operations and financial condition
10. 107Taxing authorities may successfully assert that we should have collected or in the future should collect sales and use, value added or similar taxes, and any such assessments could adversely affect our business, financial condition, and results of operations